Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2026-06-12 17:09:52 ET · period of report 2026-06-11 · accession 0001193125-26-269694 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-12 17:09 | 2026-06-11+ | SNDX | Botwood Nicholas A.J. | CMO, Head of R, D | M - OptEx | $13.82 | +53.8K | 92.1K | +140% | +$742.8K |
| DMT | 2026-06-12 17:09 | 2026-06-11+ | SNDX | Botwood Nicholas A.J. | CMO, Head of R, D | S - Sale+OE | $18.07 | -65.5K | 60.9K | -52% | -$1.18M |
| DMT | 2026-06-12 17:09 | 2026-06-11+ | SNDX | Botwood Nicholas A.J. | CMO, Head of R, D | M - OptEx | $0.00 | +53.8K | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-11 | M | A | 22,515 | $13.82 | 95,165 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-11 | S | D | 34,280 | $18.00 | 60,885 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested. (F2) These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date. |
| 3 | Common | Common Stock | 2026-06-12 | M | A | 31,235 | $13.82 | 92,120 | D | — | — | |
| 4 | Common | Common Stock | 2026-06-12 | S | D | 31,235 | $18.14 | 60,885 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested. (F3) These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date. |
| 5 | Derivative | Stock options (Right to buy) | 2026-06-11 | M | A | 22,515 | $0.00 | 0 | D | $13.82 · — to 2035-05-31 | 22,515 Common Stock | (F4) The shares sold in this transaction were fully vested. |
| 6 | Derivative | Stock options (Right to buy) | 2026-06-12 | M | A | 31,235 | $0.00 | 0 | D | $13.82 · — to 2035-05-31 | 31,235 Common Stock | (F4) The shares sold in this transaction were fully vested. |